ALMS Earnings Date: Nov 12, 2026 (Estimated) — Alumis Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ALMS's next earnings date?
Alumis Inc. (ALMS) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.73 on revenue of $1.9M.
How did ALMS do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Alumis Inc. posted EPS of -$1.11 versus the -$0.77 estimate, a miss of 56.3%. Revenue was $1.7M against a $3.7M estimate. The stock's 1-day post-earnings move was +3.7%.
How much does ALMS stock move after earnings?
ALMS beat EPS estimates in 4 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 6.2% (up or down) in the day after earnings.
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.77 | -1.11 | -56.34% | $1.7M | ❌ Miss | +3.69% | -6.35% | -62.23% |
| 2026-05-14 | Q1 2026 | -0.78 | -0.74 | +5.13% | $1.7M | ✅ Beat | -7.15% | -9.99% | -6.62% |
| 2026-03-19 | Q4 2025 | -0.97 | -0.94 | +3.09% | $1.9M | ✅ Beat | -1.26% | +3.70% | -2.64% |
| 2025-11-13 | Q3 2025 | -0.97 | -1.06 | -9.28% | $2.1M | ❌ Miss | +4.55% | +31.06% | +114.20% |
| 2025-08-13 | Q2 2025 | -1.28 | -1.27 | +0.78% | $2.7M | ✅ Beat | -0.68% | -0.23% | -1.13% |
| 2025-03-19 | Q4 2024 | -1.44 | -1.74 | -20.83% | $0 | ❌ Miss | -18.31% | +12.59% | +14.42% |
| 2024-11-13 | Q3 2024 | -4.50 | -1.73 | +61.56% | $0 | ✅ Beat | -12.95% | -10.82% | -22.39% |
| 2024-08-13 | Q2 2024 | — | -23.10 | — | $0 | — | +1.36% | +3.67% | -10.21% |
Showing last 8 quarters.